Gydrelle

Gydrelle is a vaginal formulation that contains the estrogen estriol and is marketed in the European Union as a hormone‑therapy product. The preparation delivers a weak estrogenic effect by binding to estrogen receptors in vaginal tissue. Gydrelle is intended for local use, is supplied without a specified strength, and is typically prescribed by healthcare professionals for conditions associated with estrogen deficiency in post‑menopausal women.

Gydrelle is used in clinical practice to address estrogen‑related changes of the lower genital tract.

- Relief of vaginal dryness associated with vulvovaginal atrophy. - Reduction of itching, burning, or irritation in the vaginal area. - Improvement of urinary symptoms linked to atrophic changes. - Management of mild menopausal symptoms such as discomfort during intercourse.

Side effects reported with vaginal estriol products vary in frequency and severity.

Common: - Mild vaginal irritation or discharge. - Slight spotting or spotting after intercourse. - Temporary increase in vaginal discharge.

Serious: - Allergic reaction such as rash, swelling, or difficulty breathing. - Unexplained vaginal bleeding. - Signs of estrogen‑dependent tumor growth.

Before initiating Gydrelle, certain precautions should be considered to ensure safe use.

- Not recommended for women with known estrogen‑dependent cancers. - Use caution if a history of blood clots or thromboembolic disorders exists. - Avoid if active vaginal infection or unexplained vaginal bleeding is present. - Discuss use with a healthcare provider during pregnancy or breastfeeding, as safety data are limited. - Monitor for signs of hormonal imbalance, such as breast tenderness or mood changes.

Estriol can interact with other medications or substances that affect estrogen pathways or clotting mechanisms.

Avoid: - Combined use with systemic estrogen therapy or high‑dose hormonal contraceptives. - Concurrent use of anticoagulants that increase bleeding risk.

Use with caution: - Medications that influence liver enzymes (e.g., CYP3A4 inhibitors). - Hormone‑sensitive cancer treatments. - Herbal supplements containing phytoestrogens.